How semaglutide's mechanism of action produces weight loss

The biggest misconception: semaglutide does not simply 'suppress willpower'

One of the most common misunderstandings about semaglutide is that it works by making people too nauseated to eat. Nausea can occur, particularly early in treatment, but nausea is a side effect of the mechanism — not the mechanism itself. The actual moa of semaglutide is far more specific.

Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a hormone your gut releases naturally after eating. The natural version is cleared from your bloodstream in minutes; semaglutide has been engineered with a fatty-acid side chain that binds to albumin in the blood, extending its half-life to roughly one week. That structural change is why a single weekly injection is enough to keep GLP-1 receptors continuously activated.

Those receptors sit in several places: the hypothalamus (the brain's appetite-control centre), the brainstem, the pancreas and the gut wall. Activating them simultaneously reduces hunger signals, dampens the reward response to food, slows gastric emptying and, in people with elevated blood sugar, increases insulin release. No stimulants, no fat-blocking enzymes. The result is a measurable reduction in calorie intake because the biological drive to eat is genuinely quieter, not because the patient is pushing harder against it. Our semaglutide overview page covers how that translates to treatment eligibility and the licensed indications in the UK.

If you've been reading about this medicine and found it hard to separate the mechanism from the marketing, that's a very reasonable place to land. The science is genuinely interesting once you can see past the noise.

What GLP-1 receptor activation actually does, step by step

When semaglutide binds to hypothalamic GLP-1 receptors, it reduces the output of appetite-promoting neurons and increases the activity of satiety-promoting ones. The net effect is a lower drive to eat and an earlier sense of fullness during a meal. This is a neurobiological change, not a motivational one.

In the gut, semaglutide slows the rate at which the stomach empties into the small intestine. Food sits in the stomach longer, mechanical stretch receptors remain activated for longer, and fullness persists. For many people this means smaller portions feel satisfying, and the urge to snack between meals falls substantially. The NHS's medicines information for tirzepatide and semaglutide both describe this gastric-emptying effect as a core part of how these treatments work, and you can read the patient-facing detail on the NHS semaglutide medicines page.

In the pancreas, GLP-1 receptor activation increases insulin secretion when blood glucose is elevated and suppresses glucagon when it is not. This glucose-dependent mechanism is important: insulin is only pushed out when sugar levels are already high, which is why semaglutide alone carries a much lower risk of hypoglycaemia than some other diabetes medicines. That pancreatic effect matters most for people with type 2 diabetes, but the gut and brain effects drive the weight-loss results in people without it.

The mechanism of action for Wegovy specifically is the same as for semaglutide, because Wegovy is the brand name for the 2.4 mg weight-management formulation of semaglutide.

What the trial evidence shows for the mechanism in practice

Knowing the mechanism is one thing; seeing what it produces in real people is another. The STEP 1 trial, published in the New England Journal of Medicine, randomised 1,961 adults with obesity or overweight plus a weight-related condition to semaglutide 2.4 mg once weekly or placebo, alongside lifestyle intervention, over 68 weeks. Average weight loss in the semaglutide group was around 15% of body weight. The placebo group, receiving the same lifestyle advice, lost roughly 2.4%. The gap is the mechanism.

Importantly, weight loss in the trial was gradual and continued well beyond the first weeks, consistent with appetite suppression rather than a transient nausea effect. Participants reported eating less because they were less hungry, not because eating felt unpleasant. The STEP 1 paper in the NEJM is publicly accessible for anyone who wants to read the primary data.

NICE assessed this evidence before recommending semaglutide (as Wegovy) for weight management in the UK. The recommendation covers adults with a BMI of 35 or above and at least one weight-related condition, used within a specialist service for a maximum of two years. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. For people considering the treatment privately, a clinician at our pharmacy reviews the full clinical picture before any prescription is issued. If you want to explore whether this is the right route for you, the free consultation page walks through every step.

How the mechanism differs from tirzepatide and older medicines

Semaglutide acts on a single receptor pathway: GLP-1. Tirzepatide, licensed in the UK as Mounjaro, activates both GLP-1 and GIP receptors, a dual mechanism that appears to produce greater average weight loss in head-to-head data, including the SURMOUNT-5 trial published in 2025. That does not make semaglutide less effective in absolute terms; for many people the 2.4 mg injection or, as of summer 2026, the newly approved oral Wegovy tablet produces substantial and clinically meaningful results. If you are interested in a compounded alternative, you can find out more about how megatan semaglutide is formulated and used.

Older approaches (orlistat, for instance) work by blocking the enzyme lipase in the gut, preventing absorption of around a third of dietary fat. That is a peripheral, digestive mechanism with no central appetite effect. Phentermine-based products (not widely available in the UK) act as stimulants. Neither class touches GLP-1 receptors, which is why their efficacy profiles look so different from semaglutide's.

Understanding the moa of semaglutide also helps explain the side-effect profile. Because gastric emptying slows, nausea, vomiting and diarrhoea are the most common adverse effects, especially in the weeks after starting or after a dose increase. They arise from the same mechanism that produces weight loss, not from something going wrong. Our Wegovy 0.25 mg page covers what to expect at the start of treatment in more practical detail. For the full picture on how semaglutide behaves as a prescription medicine, see our semaglutide dosing guide or speak to the clinical team directly.